Nothing Special   »   [go: up one dir, main page]

MX2019006504A - Composicion farmaceutica de tratamiento de tumores. - Google Patents

Composicion farmaceutica de tratamiento de tumores.

Info

Publication number
MX2019006504A
MX2019006504A MX2019006504A MX2019006504A MX2019006504A MX 2019006504 A MX2019006504 A MX 2019006504A MX 2019006504 A MX2019006504 A MX 2019006504A MX 2019006504 A MX2019006504 A MX 2019006504A MX 2019006504 A MX2019006504 A MX 2019006504A
Authority
MX
Mexico
Prior art keywords
tumor
pharmaceutical composition
treating pharmaceutical
treating
lenvatinib
Prior art date
Application number
MX2019006504A
Other languages
English (en)
Inventor
Ozawa Yoichi
Hori Yusaku
Yamada Kazuhiko
Kamiyama Hiroshi
MATSUKI Masahiro
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2019006504A publication Critical patent/MX2019006504A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporciona una composición farmacéutica para tratar un tumor, que se usa en terapia de combinación de lenvatinib y (6S, 9aS)-N-bencil-8-({6-[3-(4-etilpiperazin-1-il)azetidin-1-il]piridi n-2-il}metil)-6-(2-fluoro-4-hidroxibencil)-4,7-dioxo-2-(prop-2-en -1-il)hexahidro-2H-pirazino[2,1-c] [1,2,4]triazin-1(6H)-carboxamid a.
MX2019006504A 2017-02-08 2018-02-06 Composicion farmaceutica de tratamiento de tumores. MX2019006504A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017021542 2017-02-08
PCT/JP2018/004007 WO2018147275A1 (ja) 2017-02-08 2018-02-06 腫瘍治療用医薬組成物

Publications (1)

Publication Number Publication Date
MX2019006504A true MX2019006504A (es) 2019-08-14

Family

ID=63107502

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006504A MX2019006504A (es) 2017-02-08 2018-02-06 Composicion farmaceutica de tratamiento de tumores.

Country Status (13)

Country Link
US (1) US20190388420A1 (es)
EP (1) EP3581183B1 (es)
JP (1) JP6581320B2 (es)
KR (1) KR102539920B1 (es)
CN (1) CN110072528B (es)
AU (1) AU2018219637B2 (es)
BR (1) BR112019014127A2 (es)
CA (1) CA3044658A1 (es)
ES (1) ES2971448T3 (es)
IL (1) IL267159B (es)
MX (1) MX2019006504A (es)
RU (1) RU2750539C2 (es)
WO (1) WO2018147275A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
TW202137984A (zh) * 2019-10-29 2021-10-16 日商衛材R&D企管股份有限公司 用於治療癌症之PD-1拮抗劑、VEGFR/FGFR/RET酪胺酸激酶抑制劑及CBP/β-連環蛋白抑制劑之組合
EP4364742A1 (en) * 2021-09-08 2024-05-08 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating solid tumors
WO2024209717A1 (ja) * 2023-04-06 2024-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
JP2005008534A (ja) 2003-06-17 2005-01-13 Soc De Conseils De Recherches & D'applications Scientifiques (Scras) 抗癌剤及び癌の治療方法
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
US20090209580A1 (en) 2006-05-18 2009-08-20 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
EP2288383A1 (en) 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
CA2915005C (en) 2013-06-26 2021-12-28 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
US9174998B2 (en) * 2013-12-25 2015-11-03 Eisai R&D Management Co., Ltd. (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
US10117872B2 (en) 2014-03-28 2018-11-06 Università Degli Studi Di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
ES2886107T3 (es) * 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
KR102559211B1 (ko) 2015-06-23 2023-07-25 에자이 알앤드디 매니지먼트 가부시키가이샤 (6S,9aS)-N-벤질-8-({6-[3-(4-에틸피페라진-1-일)아제티딘-1-일]피리딘-2-일}메틸)-6-(2-플루오로-4-하이드록시벤질)-4,7-디옥소-2-(프로프-2-엔-1-일)헥사하이드로-2H-피라지노[2,1-c][1,2,4]트리아진-1(6H)-카복사마이드의 결정

Also Published As

Publication number Publication date
EP3581183B1 (en) 2023-11-29
EP3581183A4 (en) 2020-12-09
ES2971448T3 (es) 2024-06-05
KR102539920B1 (ko) 2023-06-05
CA3044658A1 (en) 2018-08-16
IL267159A (en) 2019-10-31
RU2019120680A3 (es) 2021-03-09
BR112019014127A2 (pt) 2020-02-11
RU2019120680A (ru) 2021-03-09
WO2018147275A1 (ja) 2018-08-16
KR20190110525A (ko) 2019-09-30
JP6581320B2 (ja) 2019-09-25
JPWO2018147275A1 (ja) 2019-11-07
IL267159B (en) 2022-05-01
CN110072528A (zh) 2019-07-30
EP3581183A1 (en) 2019-12-18
CN110072528B (zh) 2022-04-26
RU2750539C2 (ru) 2021-06-29
US20190388420A1 (en) 2019-12-26
AU2018219637A1 (en) 2019-05-23
AU2018219637B2 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
MX2019006504A (es) Composicion farmaceutica de tratamiento de tumores.
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
IL255901B (en) Crystal of (6s,9as)–n–benzyl–8–({6–[3–(4–ethylpiperazin–1–yl)azetidin–1–yl]pyridin–2–yl}methyl)–6–(2– fluoro-4-hyfroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h )-carboxamide
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX368066B (es) Derivados de quinazolin-4-ona sustituida.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2015017964A (es) Inhibidores de bromodominio.
MX2015002177A (es) Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas.
GEP20186878B (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
MX2018001790A (es) Articulo absorbente con cuerpo absorbente que proporciona mejor acceso a la bolsa de contencion del miembro de contencion de la cintura.
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
UA118278C2 (uk) Гідроксиформамідні похідні та їх застосування
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
EP3294246A4 (en) ABSORBENT ARTICLE IN THE FORM OF A PANTY, SUCH AS A CULOTTE LAYER, A HYGIENIC PANTY OR A PANT OF INCONTINENCE
PT3774795T (pt) 4-(1h-imidazol-5-il)-1h-pirrolo[2,3-b]piridinas para utilização no tratamento de leucemias, linfomas e tumores sólidos
MX2020010673A (es) Formulaciones de apixaban.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
UA87715U (uk) Спосіб лікування хворих початковою або розвиненою непроліферативною діабетичною ретинопатією